Retromer Therapeutics is developing novel therapeutics to treat neurodegenerative diseases.
Pre-clinical
OVERVIEW:
Retromer Therapeutics is a pre-clinical stage biotech company pioneering a new class of therapeutics to treat neurodegenerative diseases by resorting the function of the endolysosmal trafficking system with preclinical programs in neurodegenerative disorders including Alzheimer’s disease.
Sources:
Medline, National Institute of Environmental Health Science, Alzheimer’s Disease Association, Parkinson’s Foundation
Type 1 diabetes
Metrics:
In the United States, as many as 6.2 M people may have Alzheimer’s disease.
Occur when nerve cells in the brain or peripheral nervous system lose function over time and ultimately die.
REASONS
TO BELIEVE
- There is tremendous need for safe & efficacious therapeutics addressing neurodegenerative diseases.
- Althrough certain treatments may help relieve some of the physical or mental symptoms associated with neurodegenrative diseases slowing ther progression is not currently possible and no cures exits.
- The lack of avaliable treatments underscores the importance of accelerating novel approches to a disease modifying therapeutic.
- The likelihood of developing a neurodegenerative disease rises dramatically with age. In the coming decades, more Americans may be affected by neurodegenerative diseases especially as life expectancy increases.
